List view / Grid view
Here, Dr Michael Irizarry, Eisai’s Senior Vice President of Clinical Research and Deputy Chief Clinical Officer for Alzheimer’s Disease and Brain Health discusses its highly anticipated Alzheimer’s drug, lecanemab.
A Marketing Authorisation Application for lecanemab to treat Alzheimer's has been submitted to the European Medicines Agency.
Lecanemab for Alzheimer's and the first potential gene therapy primed for US launch for haemophilia A are two potential blockbuster Drugs to Watch™, says a 2023 report.
Alzheimer’s drug Leqembi has been accepted via the US Food and Drug Administration (FDA)’s Accelerated Approval pathway.
Four Japanese pharmaceutical companies agree to collaborate on promoting more sustainable pharmaceutical packaging.
Full study results of Eisai’s Phase III Alzheimer's study suggest lecanemab could slow disease progression.
Phase III trial confirmed Eisai’s lecanemab significantly decreased cognitive decline in patients with mild Alzheimer’s disease.
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
After clinical trials showed an increased risk of cancer in patients taking Belviq, the FDA has recommended the withdrawal of the drug from the US market.
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in…
8 July 2016 | By Victoria White, Digital Content Producer
Eisai has expressed concern that patients in England and Wales will have to wait three years to access Lenvatinib due to a ‘black hole’ in the CDF process...
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
